These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15794741)

  • 1. CHARMed - the effects of candesartan in heart failure.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Mar; 6(3):513-6. PubMed ID: 15794741
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Candesartan in heart failure: assessment of reduction in mortality and morbidity].
    Tsutsui H
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():507-12. PubMed ID: 17508585
    [No Abstract]   [Full Text] [Related]  

  • 4. [Angiotensin receptor blockers in heart failure. CHARM Study].
    Kochsiek K
    Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
    [No Abstract]   [Full Text] [Related]  

  • 5. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H; Komuro I
    Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cardioprotection by means of Candesartan in cardiac insufficiency. CHARM overall partial evaluation (Candesartan in heart failure assessment of reduction in mortality and morbidity)].
    Tschöpe C; Schultheiss HP
    Internist (Berl); 2006 Oct; 47(10):1084-6. PubMed ID: 16988804
    [No Abstract]   [Full Text] [Related]  

  • 8. [Conclusions from CHARM interview with Prof. Veselin Mitrovich, Bad Nauheim. Strong evidence: more help for weak hearts].
    Mitrovic V
    MMW Fortschr Med; 2005 Mar; 147(13):48-9. PubMed ID: 15832762
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.
    Gremmler B; Kisters K; Kunert M; Schleiting H; Ulbricht LJ
    Acta Cardiol; 2007 Aug; 62(4):321-8. PubMed ID: 17824291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure.
    Meredith PA; Jarvis SC
    Int J Clin Pract; 2011 Aug; 65(8):911; author reply 912. PubMed ID: 21762314
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
    Demers C; McMurray JJ; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Ostergren J; Michelson EL; Johansson PA; Wang D; Yusuf S;
    JAMA; 2005 Oct; 294(14):1794-8. PubMed ID: 16219883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candesartan in heart failure.
    Ripley TL; Chonlahan JS; Germany RE
    Clin Interv Aging; 2006; 1(4):357-66. PubMed ID: 18046913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
    White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
    J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does slow and steady win the race?
    Howlett JG
    J Am Coll Cardiol; 2012 May; 59(20):1796-8. PubMed ID: 22575318
    [No Abstract]   [Full Text] [Related]  

  • 17. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
    Hennekens CH; Kowalczykowski M; Hollar D
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?
    Pitt B
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):70-1. PubMed ID: 16265371
    [No Abstract]   [Full Text] [Related]  

  • 19. Improving outcomes in chronic heart failure.
    Komajda M
    Drugs Today (Barc); 2006 Dec; 42 Suppl C():29-36. PubMed ID: 17245479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
    Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.